CA2972438C - Traitement prophylactique par laser a micro-impulsions infraliminaire pour maladies evolutives chroniques de la retine - Google Patents
Traitement prophylactique par laser a micro-impulsions infraliminaire pour maladies evolutives chroniques de la retine Download PDFInfo
- Publication number
- CA2972438C CA2972438C CA2972438A CA2972438A CA2972438C CA 2972438 C CA2972438 C CA 2972438C CA 2972438 A CA2972438 A CA 2972438A CA 2972438 A CA2972438 A CA 2972438A CA 2972438 C CA2972438 C CA 2972438C
- Authority
- CA
- Canada
- Prior art keywords
- retinal
- laser light
- laser
- treatment
- para
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000017442 Retinal disease Diseases 0.000 title claims abstract description 40
- 230000000750 progressive effect Effects 0.000 title description 10
- 230000001684 chronic effect Effects 0.000 title description 9
- 238000011321 prophylaxis Methods 0.000 title description 6
- 238000011282 treatment Methods 0.000 claims abstract description 115
- 230000002207 retinal effect Effects 0.000 claims abstract description 87
- 210000001525 retina Anatomy 0.000 claims abstract description 68
- 230000001681 protective effect Effects 0.000 claims abstract description 10
- 230000005856 abnormality Effects 0.000 claims abstract description 8
- 238000003384 imaging method Methods 0.000 claims abstract description 8
- 208000024891 symptom Diseases 0.000 claims abstract description 7
- 230000000649 photocoagulation Effects 0.000 claims description 48
- 238000012360 testing method Methods 0.000 claims description 47
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 24
- 208000002780 macular degeneration Diseases 0.000 claims description 23
- 230000006378 damage Effects 0.000 claims description 19
- 230000000451 tissue damage Effects 0.000 claims description 9
- 231100000827 tissue damage Toxicity 0.000 claims description 9
- 230000033001 locomotion Effects 0.000 claims description 4
- 230000004517 retinal physiology Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 26
- 230000004243 retinal function Effects 0.000 abstract description 15
- 230000008569 process Effects 0.000 abstract description 13
- 230000004382 visual function Effects 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 description 37
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 29
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 29
- 206010012689 Diabetic retinopathy Diseases 0.000 description 25
- 230000003287 optical effect Effects 0.000 description 23
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 230000004304 visual acuity Effects 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 238000002203 pretreatment Methods 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000004393 visual impairment Effects 0.000 description 16
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 15
- 201000011190 diabetic macular edema Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 230000001976 improved effect Effects 0.000 description 12
- 238000001126 phototherapy Methods 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 230000004438 eyesight Effects 0.000 description 10
- 238000013532 laser treatment Methods 0.000 description 10
- 206010057430 Retinal injury Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 208000001344 Macular Edema Diseases 0.000 description 6
- 206010025421 Macule Diseases 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 206010025415 Macular oedema Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 201000010230 macular retinal edema Diseases 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000037390 scarring Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 201000007737 Retinal degeneration Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000017525 heat dissipation Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000007831 electrophysiology Effects 0.000 description 3
- 238000002001 electrophysiology Methods 0.000 description 3
- 238000002571 electroretinography Methods 0.000 description 3
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000004258 retinal degeneration Effects 0.000 description 3
- 238000011268 retreatment Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 235000005459 Digitaria exilis Nutrition 0.000 description 2
- 240000008570 Digitaria exilis Species 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 208000014139 Retinal vascular disease Diseases 0.000 description 2
- 208000027073 Stargardt disease Diseases 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004637 cellular stress Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 231100001160 nonlethal Toxicity 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002301 subretinal fluid Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100135611 Arabidopsis thaliana PAP12 gene Proteins 0.000 description 1
- 206010005184 Blindness transient Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010008783 Choroidal detachment Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 208000008069 Geographic Atrophy Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 241000407429 Maja Species 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010038895 Retinal scar Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000013533 micropulse laser treatment Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000009015 preretinal fibrosis Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004253 retinal exposure Effects 0.000 description 1
- 230000004262 retinal health Effects 0.000 description 1
- 230000004286 retinal pathology Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 201000003772 severe nonproliferative diabetic retinopathy Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000007853 structural degeneration Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00821—Methods or devices for eye surgery using laser for coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00863—Retina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00897—Scanning mechanisms or algorithms
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Optics & Photonics (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une méthode de traitement d'un il afin d'arrêter ou de retarder l'apparition ou d'atténuer les symptômes de maladies de la rétine consistant à déterminer que l'il présente un risque de développer une maladie de la rétine avant l'apparition d'anomalies détectables dans l'imagerie de la rétine. Un faisceau de lumière laser généré permet de fournir un traitement préventif et de protection des tissus de la rétine de l'il. Au moins une partie des tissus de la rétine est exposée au faisceau de lumière laser sans léser les tissus. La rétine peut être traitée de nouveau selon un programme défini ou de manière périodique en fonction de la détermination selon laquelle la rétine du patient doit être traitée de nouveau par la surveillance d'une fonction ou d'un état visuel et/ou de la rétine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3022624A CA3022624A1 (fr) | 2015-01-28 | 2015-11-16 | Traitement prophylactique par laser a micro-impulsions infraliminaire pour maladies evolutives chroniques de la retine |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/607,959 | 2015-01-28 | ||
| US14/607,959 US9168174B2 (en) | 2012-05-25 | 2015-01-28 | Process for restoring responsiveness to medication in tissue of living organisms |
| US14/921,890 US9381116B2 (en) | 2012-05-25 | 2015-10-23 | Subthreshold micropulse laser prophylactic treatment for chronic progressive retinal diseases |
| US14/921,890 | 2015-10-23 | ||
| PCT/US2015/060836 WO2016122750A1 (fr) | 2015-01-28 | 2015-11-16 | Traitement prophylactique par laser à micro-impulsions infraliminaire pour maladies évolutives chroniques de la rétine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022624A Division CA3022624A1 (fr) | 2015-01-28 | 2015-11-16 | Traitement prophylactique par laser a micro-impulsions infraliminaire pour maladies evolutives chroniques de la retine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2972438A1 CA2972438A1 (fr) | 2016-08-04 |
| CA2972438C true CA2972438C (fr) | 2020-09-15 |
Family
ID=56544129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022624A Abandoned CA3022624A1 (fr) | 2015-01-28 | 2015-11-16 | Traitement prophylactique par laser a micro-impulsions infraliminaire pour maladies evolutives chroniques de la retine |
| CA2972438A Active CA2972438C (fr) | 2015-01-28 | 2015-11-16 | Traitement prophylactique par laser a micro-impulsions infraliminaire pour maladies evolutives chroniques de la retine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022624A Abandoned CA3022624A1 (fr) | 2015-01-28 | 2015-11-16 | Traitement prophylactique par laser a micro-impulsions infraliminaire pour maladies evolutives chroniques de la retine |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3250167A4 (fr) |
| JP (1) | JP2018503432A (fr) |
| CN (1) | CN107205848A (fr) |
| AU (1) | AU2015380409B2 (fr) |
| BR (1) | BR112017016267A2 (fr) |
| CA (2) | CA3022624A1 (fr) |
| WO (1) | WO2016122750A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10973683B2 (en) * | 2017-01-31 | 2021-04-13 | Amo Development, Llc | Methods and systems for laser ophthalmic surgery that provide for iris exposures below a predetermined exposure limit |
| RU2647803C1 (ru) * | 2017-03-29 | 2018-03-19 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ хирургического лечения рубцовой стадии субретинальной неоваскулярной мембраны |
| CN111343936B (zh) * | 2017-11-15 | 2024-03-22 | 奥哈伊视网膜技术有限责任公司 | 利用能量治疗生物组织的方法及系统 |
| RU2668707C1 (ru) * | 2018-02-15 | 2018-10-02 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лазерного лечения макулярного отека, возникающего после операции по поводу удаления хрусталика |
| CN111523629B (zh) * | 2020-04-14 | 2023-01-10 | 郑州大学 | 一种二维码的视觉优化方法、装置、电子设备及存储介质 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5921981A (en) | 1995-11-09 | 1999-07-13 | Alcon Laboratories, Inc. | Multi-spot laser surgery |
| US6610292B2 (en) * | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
| US7309487B2 (en) * | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
| US10238541B2 (en) | 2011-10-19 | 2019-03-26 | Iridex Corporation | Short duration pulse grid pattern laser treatment and methods |
| US9278029B2 (en) * | 2011-10-19 | 2016-03-08 | Iridex Corporation | Short duration pulse grid pattern laser treatment and methods |
| US9101447B2 (en) * | 2011-10-20 | 2015-08-11 | Topcon Medical Laser Systems, Inc. | Endpoint-managed photocoagulation |
| US9381115B2 (en) | 2012-05-25 | 2016-07-05 | Ojai Retinal Technology, Llc | System and process for retina phototherapy |
| US10219947B2 (en) * | 2012-05-25 | 2019-03-05 | Ojai Retinal Technology, Llc | System and process for retina phototherapy |
| JP6439271B2 (ja) | 2013-04-30 | 2018-12-19 | 株式会社ニデック | レーザ治療装置 |
-
2015
- 2015-11-16 CN CN201580073106.7A patent/CN107205848A/zh active Pending
- 2015-11-16 CA CA3022624A patent/CA3022624A1/fr not_active Abandoned
- 2015-11-16 EP EP15880626.5A patent/EP3250167A4/fr active Pending
- 2015-11-16 CA CA2972438A patent/CA2972438C/fr active Active
- 2015-11-16 AU AU2015380409A patent/AU2015380409B2/en active Active
- 2015-11-16 BR BR112017016267A patent/BR112017016267A2/pt not_active Application Discontinuation
- 2015-11-16 JP JP2017533199A patent/JP2018503432A/ja active Pending
- 2015-11-16 WO PCT/US2015/060836 patent/WO2016122750A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CA3022624A1 (fr) | 2016-08-04 |
| CN107205848A (zh) | 2017-09-26 |
| JP2018503432A (ja) | 2018-02-08 |
| CA2972438A1 (fr) | 2016-08-04 |
| WO2016122750A1 (fr) | 2016-08-04 |
| EP3250167A1 (fr) | 2017-12-06 |
| AU2015380409A1 (en) | 2017-07-20 |
| EP3250167A4 (fr) | 2018-08-01 |
| AU2015380409B2 (en) | 2018-10-18 |
| BR112017016267A2 (pt) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9381116B2 (en) | Subthreshold micropulse laser prophylactic treatment for chronic progressive retinal diseases | |
| US10278865B2 (en) | Process for neuroprotective therapy for glaucoma | |
| US9168174B2 (en) | Process for restoring responsiveness to medication in tissue of living organisms | |
| AU2021215167B2 (en) | System and process for retina phototherapy | |
| CA2972438C (fr) | Traitement prophylactique par laser a micro-impulsions infraliminaire pour maladies evolutives chroniques de la retine | |
| EP3451983B1 (fr) | Système pour une thérapie neuroprotectrice pour le glaucome | |
| AU2015380376B2 (en) | Process for restoring responsiveness to medication in tissue of living organisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180108 |